££......Osmetech ......Smell the Success.....££

Current Trading and Prospects
Critical Care Division
Sales in the current year for the Division’s OPTI™ range of blood gas analysis products have remained strong in both the human and veterinary markets. The Board expects the strong levels of demand in the Critical Care Division to continue and therefore it to be another year of significant progress for the Division.
Molecular Diagnostics Division

Osmetech continues to make significant progress with the commercialisation of its molecular diagnostics products. The Group has been successful in securing a number of customers for the Group's FDA approved eSensor™ Cystic Fibrosis Carrier Detection test and eSensor™ 4800 DNA Detection instrument. For example, a customer has recently signed a two year contract with minimum consumable usage rates of approximately $75,000 per year and the Board believes that its actual usage rates may soon be in the region of $250,000 per annum. The manufacturing scale-up process and product performance have been satisfactory throughout this critical initial sales period and the Directors are confident that the Group will be able to expand sales moving into next year as the installed base of instruments increases.

OPTI GENE™ sales are expected to commence early in 2007 and OPTI TUBE™ has generated much interest since its recent launch and a number of successful customer trials are yielding positive results that should lead to sales in the near future.
Outlook
just something to look at